ADMA, MDA and PTX-3 were the markers responsible for the improvement of endothelial dysfunction in patients using these three products with anti-inflammatory, anti-oxidant and anti-atherosclerotic properties. This evidence concerns the gene PTX3 and endothelial dysfunction.